HomeGNMSF • OTCMKTS
add
Genmab A/S
Previous close
$276.47
Day range
$282.69 - $301.37
Year range
$262.00 - $426.50
Market cap
19.82B USD
Avg Volume
592.00
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
In the news
Financials
Income Statement
Revenue
Net income
| (DKK) | Mar 2024info | Y/Y change |
|---|---|---|
Revenue | 4.14B | 45.16% |
Operating expense | 3.16B | 30.62% |
Net income | 1.32B | 486.28% |
Net profit margin | 31.98 | 303.79% |
Earnings per share | — | — |
EBITDA | 861.00M | 66.22% |
Effective tax rate | 22.79% | — |
Balance Sheet
Total assets
Total liabilities
| (DKK) | Mar 2024info | Y/Y change |
|---|---|---|
Cash and short-term investments | 29.58B | 20.53% |
Total assets | 36.68B | 20.68% |
Total liabilities | 4.18B | 30.56% |
Total equity | 32.50B | — |
Shares outstanding | 65.30M | — |
Price to book | 0.56 | — |
Return on assets | 5.56% | — |
Return on capital | 6.08% | — |
Cash Flow
Net change in cash
| (DKK) | Mar 2024info | Y/Y change |
|---|---|---|
Net income | 1.32B | 486.28% |
Cash from operations | 1.51B | -53.23% |
Cash from investing | -1.44B | -10,984.62% |
Cash from financing | -595.00M | 2.62% |
Net change in cash | -197.00M | -108.23% |
Free cash flow | 956.50M | -65.65% |
About
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund. The company is based in Copenhagen, Denmark – internationally, it operates through the subsidiaries Genmab B.V. in Utrecht, The Netherlands, Genmab U.S., Inc. in Princeton, USA, and Genmab K.K. in Tokyo, Japan. Genmab is a dual-listed company with shares traded on both the Copenhagen Stock Exchange in Denmark and the NASDAQ Global Select Market in the US.
The company has 8 approved antibodies used in 8 marketed products, covering cancer indications and autoimmune diseases.
Proprietary, marketed with partners:
Epkinly/Tepkinly for the treatment of Relapsed/refractory diffuse large B-cell lymphoma
Tivdak for the treatment of previously treated recurrent or metastatic cervical cancer
Marketed by partners:
Darzalex (IV) / Darzalex Faspro for the treatment of all stages of multiple myeloma as combination therapy or monotherapy, and for the treatment of newly diagnosed amyloid light-chain amyloidosis
Kesimpta for the treatment of relapsing remitting multiple sclerosis
Rybrevant for the treatment of non-small-cell lung cancer Wikipedia
Founded
1999
Website
Employees
2,286
